GlassScriptPhysician profile
Cynthia Davis
NPI 1164918546
$2,058.26
in general payments reported to CMS, 2019-2025
28 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $741 · 2023: $450 · 2024: $362 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $371.93 | 2022-2025 | Darzalex, Carvykti, Rybrevant |
| Daiichi Sankyo INC. | $289.78 | 2021-2025 | Enhertu |
| Eisai INC. | $242.99 | 2021-2024 | |
| Novocure INC. | $158.89 | 2022-2023 | Optune |
| Novartis Pharmaceuticals Corporation | $132.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.57 | 2023-2025 | Calquence, Tagrisso |
| Tempus Ai, INC | $100.00 | 2024 | |
| Genzyme Corporation | $85.14 | 2021-2023 | |
| Epizyme, INC. | $64.99 | 2021 | |
| Amgen INC. | $46.24 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $42.40 | 2021 | |
| Merck Sharp & Dohme LLC | $41.46 | 2021-2024 | Keytruda |
| Servier Pharmaceuticals LLC | $40.91 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $39.87 | 2021-2022 | |
| Genentech USA, INC. | $31.65 | 2023-2024 | Venclexta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.38 | 2022 | |
| Taiho Oncology, INC. | $27.12 | 2025 | |
| Rigel Pharmaceuticals, INC. | $24.24 | 2022 | |
| Coherus Oncology, INC. | $21.84 | 2021 | |
| Iovance Biotherapeutics, INC. | $19.49 | 2025 | Amtagvi |
| Abbvie INC. | $18.86 | 2025 | |
| Acrotech Biopharma INC. | $18.75 | 2021 | |
| Incyte Corporation | $18.46 | 2022 | |
| Lundbeck LLC | $16.61 | 2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $16.08 | 2025 | |
| Octapharma USA, INC. | $15.47 | 2023 | Panzyga |
| Beigene USA, INC. | $15.02 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.74 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.